Lakefront Biotherapeutics American Depositary Shares LKFT
i
Market datapartial · fetched 2026-11-04T09:55:24.574Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:00.707281568Z
FundamentalsAlpha Vantage · unavailable
Lakefront Biotherapeutics American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 30.03 | 130.7% | 14.2% | |||
| 40Δ | 30.53 | 121.4% | 12.8% | |||
| 45Δ | 34.77 | 126.2% | 15.8% | 31.03 | 112.0% | 11.5% |
| 50Δ | 33.99 | 114.3% | 13.5% | 31.52 | 102.6% | 10.1% |
| 55Δ | 33.21 | 102.3% | 11.2% | 32.02 | 93.2% | 8.7% |
| 60Δ | 32.43 | 90.4% | 9.0% | 32.51 | 83.9% | 7.3% |
| 65Δ | 31.65 | 78.4% | 6.7% | 33.01 | 74.5% | 5.9% |
| 70Δ | 30.87 | 66.5% | 4.4% | 33.50 | 65.1% | 4.6% |
| 75Δ | 30.09 | 54.6% | 2.1% | 34.00 | 55.8% | 3.2% |
| 80Δ | 34.49 | 46.4% | 1.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.03
- IV
- 130.7%
- B/E move
- 14.2%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.53
- IV
- 121.4%
- B/E move
- 12.8%
45Δ
- Pseudo strike
- 34.77
- IV
- 126.2%
- B/E move
- 15.8%
- Pseudo strike
- 31.03
- IV
- 112.0%
- B/E move
- 11.5%
50Δ
- Pseudo strike
- 33.99
- IV
- 114.3%
- B/E move
- 13.5%
- Pseudo strike
- 31.52
- IV
- 102.6%
- B/E move
- 10.1%
55Δ
- Pseudo strike
- 33.21
- IV
- 102.3%
- B/E move
- 11.2%
- Pseudo strike
- 32.02
- IV
- 93.2%
- B/E move
- 8.7%
60Δ
- Pseudo strike
- 32.43
- IV
- 90.4%
- B/E move
- 9.0%
- Pseudo strike
- 32.51
- IV
- 83.9%
- B/E move
- 7.3%
65Δ
- Pseudo strike
- 31.65
- IV
- 78.4%
- B/E move
- 6.7%
- Pseudo strike
- 33.01
- IV
- 74.5%
- B/E move
- 5.9%
70Δ
- Pseudo strike
- 30.87
- IV
- 66.5%
- B/E move
- 4.4%
- Pseudo strike
- 33.50
- IV
- 65.1%
- B/E move
- 4.6%
75Δ
- Pseudo strike
- 30.09
- IV
- 54.6%
- B/E move
- 2.1%
- Pseudo strike
- 34.00
- IV
- 55.8%
- B/E move
- 3.2%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 34.49
- IV
- 46.4%
- B/E move
- 1.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 49.40% | |
| 53.32% | |
| 48.34% | |
| 54.98% | |
| 58.17% | |
| 59.12% |
Biotechnology
LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd,…
More →LXEO
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
More →LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in…
More →LYEL
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South…
More →MANE
Description unavailable
More →MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic…
More →